TriangleMosunetuzumab + Chemotherapy (NCT06249191)
Mosunetuzumab + Chemotherapy trial for C-Myc Rearranged High-Grade B-Cell Lymphoma or DLBCL (NCT06249191). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for previously untreated high grade B cell lymphoma or diffuse large B cell lymphoma with a c-Myc rearrangement, in adults 18 to 75.
The idea: add mosunetuzumab, an antibody, to chemotherapy. It is combined with dose-adjusted EPOCH chemotherapy. Mosunetuzumab may help the immune system attack the cancer.
This phase 1 and 2 study checks safety first, then how many patients reach a complete response on a PET scan. It plans 40 patients. At OHSU Knight Cancer Institute in Portland, Oregon, Stephen Spurgeon leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.